Access to HCV Treatment in Federal Institutions

Event Information

Share this event

Date and Time

Event description

Description

Access to HCV Treatment in Federal Institutions

Join CTAC Policy Researcher Amanda Fletcher's Webinar to Learn More About the Prevalence of hepatitis C in Canada's Federal Institutions.

HCV impacts between 250,000-300,000 Canadians, among whom at least 44% are undiagnosed and untreated. While the national HCV burden among Canadians is approximately 1%, the prevalence of HCV in correctional institutions is estimated to be between 20 and 40%. This webinar will focus on issues and recommendations around access to HCV treatment in federal institutions and address questions like: How has treatment, traditionally, been administered? What are the factors behind such a high HCV prevalence rate? What kind of preventative measures can be taken? How have CSC’s drug eligibility restrictions changed, and what does this mean for HCV treatment within the institutional setting?

Learn more about screening; treatment; harm reduction; social determinanents of health (gender, mental health/substance abuse); Correctional Service Canada's new and less restrictive eligibility requirements around fibrosis scores; and, finally, CTAC's recommendations for increasing treatment access.

Don't delay. Register now!

On the day of the event, you will need to log on to the webinar at http://ctac.adobeconnect.com/hepCprison and dial in for the audio toll-free at 877-473-4906 with conference code 4564615148

Date and Time

Save This Event

Event Saved